肺纤方对博莱霉素致肺纤维化大鼠一般情况和肺组织形态学的影响  

Effect of Formula for Lung Fibrosis on general conditions and pulmonary histomorphology of rats with pulmonary fibrosis induced by Bleocamicina

作　　者：支开叶[1] 康永[1] 倪艳[1] 纪新华[1] 卢方晋[1] 李慧娟[1] 岳永花[1] 

机构地区：[1]山西省中医院,山西太原030012

出　　处：《现代药物与临床》2012年第5期451-456,共6页Drugs & Clinic

基　　金：山西省科技攻关项目(20090311055-2)

摘　　要：目的观察肺纤方对博来霉素造模的肺纤维化大鼠肺组织病理形态发展的影响。方法 144只健康Wistar大鼠随机分成对照组,模型组,阳性组,肺纤方高、中、低剂量组,每组各24只,按Szapiel等法建立模型,次日ig给药,肺纤方高、中、低剂量(3.2、1.6、0.8g/kg)组均为10mL/kg药液ig给药,阳性对照组用醋酸泼尼松混悬液(6mg/kg)ig给药,对照组与模型组ig等量生理盐水,1次/d,给药周期21d。分别在造模7、14、21d后取材,前后期各随机杀检10只,中期杀检4只对照验证。结果与模型对照组相比,肺纤方高剂量组在改善大鼠外观、体质量、肺系数、肺脏病理组织形态学等方面效果较好(P<0.05或P<0.01),中剂量组几乎与阳性对照组作用相当,而阳性对照组先期作用好于治疗组,但中后期时肺纤方高剂量组的疗效明显好于阳性组,说明肺纤方抗大鼠肺纤维化病变的长期疗效优于阳性组。结论肺纤方是防治肺纤维化的一种有效方剂,对博莱霉素致大鼠肺损伤具有一定的保护作用,对肺纤维化具有干预作用,且呈现一定的量效关系。Objective To observe the curative effect of Formula for Lung Fibrosis on pulmonary fibrosis of rat model induced by Bleocamicina.. Methods Healthy Wistar rats （144） were randomly divided into six groups： control group, model group, prednisone acetate （PA, positive control） group, high-, mid-, and low-dose Formula for Lung Fibrosis groups, and there were 24 rats in each group. The rat model was established by Szapiel＇s method. On the next day, the three treatment groups were ig administrated with high-, mid-, and low-dose Formula for Lung Fibrosis （3.2, 1.6, and 0.8 g/kg, 10 mL/kg body weight）; The rats in PA group were ig administrated with PA （6 mg/kg）; And the rats of control group and model group were ig administrated with physiological saline at the same dose, once daily for 21 d. After 7, 14, and 21 days of model establishment, 10 rats, 4 rats, and 10 rats were randomly sacrificed, respectively, and the materials were drawn, observed, recorded, and analyzed. Results Compared with the model group, high-dose Formula for Lung Fibrosis showed the significant difference on improving rat appearance, body weight, lung coefficient, and pathological histomorphology （P 〈 0.05 or 0.01）. Mid-dose Formula for Lung Fibrosis had the same effect as PA group almost, and PA group was better than treatment group in beginning stage but worse in intermediate and later stages. This directed that high-dose Formula for Lung Fibrosis had better effect than PA group markedly, and the long-term effect of Formula for Lung Fibrosis was superior to PA. Conclusion Formula for Lung Fibrosis is an effective formula in treating and preventing pulmonary fibrosis. It could intervene in the injury of rats caused by Bleocamicina, and show a dose-effect relationship.

关 键 词：肺纤方 博来霉素 肺纤维化 病理形态 

分 类 号：R285.5[医药卫生—中药学]